Document:

Fifth Amendment Agreement

 Exhibit 10.36 
 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* * *” and has been filed separately with the Securities and Exchange Commission pursuant to a
Confidential Treatment Application filed with the Commission. 
 FIFTH AMENDMENT AGREEMENT 

This Amendment Agreement is made effective November 17, 2011 by and among Albert Einstein College of Medicine of Yeshiva University,
a Division of Yeshiva University, a corporation organized and existing under the laws of the State of New York, having an office and place of business at 1300 Morris Park Avenue, Bronx, New York 10461 (“AECOM”), Industrial Research Ltd., a
company organized and existing under the laws of New Zealand, having an office and place of business at Gracefield Research Centre, Gracefield Road, P.O. Box 31-310, Lower Hutt, New Zealand (“Industrial”) (AECOM and Industrial are
collectively referred to herein as “Licensors”), and BioCryst Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware having an office and place of business at 2190 Parkway Lake Drive,
Birmingham, Alabama 35244 (“Licensee”). 
 Statement 

Licensors and Licensee are parties to a License Agreement dated June 27, 2000, as amended by a First Amendment Agreement effective
July 26, 2002, a Second Amendment Agreement effective April 15, 2005, a Third Amendment Agreement effective December 11, 2009 and a Fourth Amendment Agreement effective May 5, 2010 (collectively “the License
Agreement”), and now wish to further amend the License Agreement. 
 NOW, THEREFORE, in consideration of the mutual
covenants contained in the License Agreement and in this Fifth Amendment Agreement and other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 

 

	 	1.	Paragraph 6.02 of the License Agreement is hereby amended to read in its entirety as follows: 

6.02 (a) Licensee shall pay to Licensors * * * percent (* * *%) of Net Proceeds. 

 

	 	(b)	Licensee shall pay to Licensors * * * percent (* * * %) of Sublicensee Royalties. 

 

	 	(c)	 Any payments due to be paid by Licensee to Licensors under paragraph 6.02(a) may be made either in cash or, at the sole option of Licensee, in
Qualified Licensee Shares or a combination of cash and Qualified Licensee Shares. Any such Qualified Licensee Shares shall be subject to the terms of Sections 6 and 8 hereof. Any Qualified Licensee Shares issued under paragraph 6.02(a) shall be
valued based on the Volume Weighted Average Price of such shares determined as of the date payment is due under paragraph 7.02 of the License Agreement. Notwithstanding the foregoing, unless otherwise agreed to by the parties, Licensee shall not be
permitted to issue Qualified Licensee Shares (i) to the extent that the number of Qualified Licensee Shares to be issued would exceed six (6) times the average daily trading volume of Licensee’s common stock for the twenty
(20) consecutive trading days ending on the trading day immediately before the date such 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* *
*” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 

 

	 	
Qualified Licensee Shares are to be issued or (ii) if Licensee does not meet the eligibility requirements for continued listing on the applicable Trading Market (as defined below).

  

	 	2.	The applicable provisions of this Fifth Amendment Agreement shall be deemed to be incorporated into the License Agreement in full and to be an integral part thereof as
though fully set forth therein. With the exception of the above amendments, all other provisions of the License Agreement shall remain in full force and effect. 

 IN WITNESS WHEREOF, the parties hereto have entered into and executed this Fifth Amendment Agreement as of the date first above written. 

 

									
	ALBERT EINSTEIN COLLEGE OF MEDICINE OF
YESHIVA UNIVERSITY	 	 	 	BIOCRYST PHARMACEUTICALS, INC.
					
	By:	 	 /s/ John L. Harb
	 		 	By:	 	 /s/ Alane Barnes

					
	Name:	 	 John L. Harb
	 		 	Name:	 	 Alane Barnes

					
	Title:	 	 Assistant Dean Scientific Operations
	 		 	Title:	 	 VP, General Counsel

				
	INDUSTRIAL RESEARCH, LTD.	 		 		 	
					
	By:	 	 /s/ Shaun Coffey
	 		 		 	
					
	Name:	 	 Shaun Coffey
	 		 		 	
					
	Title:	 	 Chief Executive
	 		 		 	

  
 -2-Seventh Amendment to Collaborative Research, Development and License Agreement

 Exhibit 10.23 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 240.24b-2. 

SEVENTH AMENDMENT TO 
 COLLABORATIVE RESEARCH, DEVELOPMENT 
 AND LICENSE AGREEMENTS

 THIS SEVENTH AMENDMENT TO COLLABORATIVE
RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTS (the “Seventh Amendment”) is entered into as of February 29, 2012 (the “Seventh
Amendment Effective Date”) by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation (“ACADIA”) with offices at 3911 Sorrento Valley Blvd., San Diego, CA 92121, and
ALLERGAN SALES, LLC, a Delaware limited liability company (“Allergan”) with offices at 2525 Dupont Drive, Irvine, CA 92612, and ALLERGAN, INC., a
Delaware corporation, solely as guarantor of the performance under this Agreement by Allergan. 

RECITALS 
 WHEREAS, the parties previously entered into that certain Collaborative Research, Development and License Agreement, dated September 24, 1997 (as amended by the First Amendment,
the Second Amendment and the Third Amendment described below, the “1997 Agreement”), pursuant to which the parties conducted collaborative research regarding, among other things, receptor selective compounds with the goal of
establishing drug discovery programs related to such receptor selective compounds; 
 WHEREAS, the parties
previously entered into that certain Collaborative Research, Development and License Agreement, dated July 26, 1999 (the “1999 Agreement”), pursuant to which the parties conducted collaborative research regarding
[...***...] muscarinic compounds for the treatment or prevention of ocular disease; 

WHEREAS, the 1997 Agreement was first amended on March 27, 2003 (the “First
Amendment”) to continue the collaboration under the 1997 Agreement with respect to alpha adrenergic receptors and on the same date the parties entered into a new Collaborative Research, Development and License Agreement (the
“2003 Agreement”) regarding ACADIA’s chemical-genomics assets; 

WHEREAS, the 1997 Agreement and the 2003 Agreement were amended on February 28, 2006 (the
“Second Amendment”) to continue the collaboration under the 1997 Agreement and the 2003 Agreement with respect to alpha adrenergic receptors and to continue to collaborate on other receptor selective compounds included in
ACADIA’s chemical-genomics assets; 
 WHEREAS, the 1997 Agreement and the 2003
Agreement were amended on March 3, 2008 (the “Third Amendment”) to continue the collaboration under the 1997 Agreement and the 2003 Agreement with respect to alpha adrenergic receptors and to continue to collaborate on
muscarinic compounds for eye-care applications; 
 WHEREAS, the 1997 Agreement and the 2003
Agreement were amended on April 22, 2009 (the “Fourth Amendment”) to finalize the research under the 1997 Agreement with respect to alpha adrenergic receptors, to continue to collaborate on 

***Confidential Treatment Requested 

  
 1 

 muscarinic compounds for eye-care applications under the 2003 Agreement, and to expand their collaboration
on [...***...] muscarinic selective compounds for eye-care indications; 
 WHEREAS,
the 1997 Agreement and the 2003 Agreement were amended on March 23, 2010 (the “Fifth Amendment”) to continue to collaborate on [...***...] muscarinic selective compounds for eye-care indications and to provide for
collaboration on muscarinic selective compounds for eye care indications or on other selective compounds included in ACADIA’s chemical-genomics assets pursuant to the 2003 Agreement; 

WHEREAS, the 1997 Agreement and the 2003 Agreement were amended on March 28, 2011 (the
“Sixth Amendment”) to continue to collaborate on [...***...] muscarinic selective compounds for eye-care indications and to provide for collaboration on muscarinic selective compounds for eye care indications or on
other selective compounds included in ACADIA’s chemical-genomics assets pursuant to the 2003 Agreement; 

WHEREAS, the parties wish to continue their research collaboration on [...***...] muscarinic selective
compounds for eye-care indications on the terms set forth below; and 
 WHEREAS, the parties
may wish to collaborate on muscarinic selective compounds for eye care indications or on other selective compounds included in ACADIA’s chemical-genomics assets pursuant to the 2003 Agreement and on the terms set forth below. 

NOW THEREFORE, in consideration of the foregoing and the covenants and premises contained in this
Seventh Amendment, the parties hereby agree as follows: 
 1.    [...***...] Expansion Program.
The parties have agreed on a pool of ten (10) compounds from ACADIA’s library of [...***...] muscarinic selective compounds from which Allergan may chose a backup compound (the “[...***...] Expansion
Program”). The current ten (10) compounds are listed on Exhibit A hereto (the “Back-up Pool”). The Research Term of the 2003 Agreement with respect to the [...***...] Expansion Program shall be
extended to cover the period beginning March 28, 2012 and ending March 27, 2013 (the “Additional Extension Period”). During the Additional Extension Period, ACADIA will provide information on compounds included in
the Back-up Pool for continued evaluation by the parties. Further, if directed by the JRC (as defined below), ACADIA shall engage in the synthesis and evaluation of additional [...***...] muscarinic selective compounds. Allergan may remove and
add compounds to the Back-up Pool from (a) ACADIA’s existing [...***...] muscarinic selective compounds (i.e., those identified prior to the Additional Extension Period), upon mutual agreement of the parties, or (b) from new
compounds synthesized at the direction of the JRC, so long as the total number of compounds in the Back-up Pool does not exceed ten (10) at any given time. Allergan may select one compound from the Back-up Pool to be treated as a Collaboration
Lead Compound (as defined in the 1999 Agreement and in addition to the compound based on [...***...], which has been advanced by the parties pursuant to the 1999 Agreement) pursuant to the terms of the 1999 Agreement. Allergan shall use
reasonable efforts to select a compound from the Back-up Pool to be treated as a second Collaboration Lead Compound prior to the end of the Additional Extension Period. Allergan’s right to so select a compound shall expire at the 

***Confidential Treatment Requested 

  
 2 

 end of the Additional Extension Period. Upon selecting a compound from the Back-up Pool to be treated as a
Collaboration Lead Compound, Allergan shall be entitled to select another compound to add to the Back-up Pool from (a) ACADIA’s existing [...***...] muscarinic selective compounds (i.e., those identified prior to the Additional
Extension Period), upon mutual agreement of the parties, or (b) from compounds synthesized at the direction of the JRC during the Additional Extension Period, so that Allergan retains ten (10) compounds within the Back-up Pool through the
end of the Additional Extension Period. If Allergan selects a Back-up Pool compound to be treated as a Collaboration Lead Compound during the Additional Extension Period, then until one year after the end of the Additional Extension Period, Allergan
may exchange such Collaboration Lead Compound for a compound within the Back-up Pool, which will then be treated as a Collaboration Lead Compound. Other than any such exchange, the Back-up Pool will not change after the end of the Additional
Extension Period. Allergan shall have no rights to the compounds remaining in the Back-up Pool, or those compounds synthesized at the direction of the JRC that are not in the Back-up Pool, on the one-year anniversary of the end of the Additional
Extension Period. 
 2.    Additional Extension Program. At the direction of the JRC, ACADIA has undertaken
discovery efforts to identify new compounds that meet mutually acceptable selection criteria for muscarinic selective compounds for [...***...]. These efforts have included and, during the Additional Extension period, will include mining of
ACADIA’s library of muscarinic compounds, re-screening where desired, in vitro pharmacology/ characterization, and supporting synthesis to enable selection of potential compounds by Allergan for in vivo pharmacology and potential development
(the “Additional Extension Program”). Any muscarinic selective compounds identified pursuant to the Additional Extension Program may be designated by Allergan as a Selected Target/Chemistry (as defined in the 2003 Agreement)
in accordance with Section 5.1 of the 2003 Agreement; provided that the right to exercise the Option (as defined in the 2003 Agreement) for such Selected Target/Chemistry shall expire on March 27, 2013, notwithstanding the Option Period
definition in Section 1.45 of the 2003 Agreement. 
 3.    FTE Funding. Research funding during the
Additional Extension Period shall be [...***...]. During the Additional Extension Period, Allergan shall fund a minimum of [...***...], and up to a maximum of [...***...]. The Joint Research Committee (the
“JRC”) shall determine the work to be done under the [...***...] Expansion Program, including the appropriate number of FTEs for such level of work. During the Additional Extension Period, Allergan, with the consent of
the JRC, also may elect to pursue the Additional Extension Program. If Allergan elects to pursue the Additional Extension Program, the JRC shall determine the number of ACADIA FTEs required for such program. The allocation of FTEs between the
Additional Extension Program, if any, and the [...***...] Expansion Program shall be decided by the JRC, provided however in the event that the parties do not agree on such allocation, notwithstanding Section 15.2 of the 2003 Agreement,
[...***...]. 
 4.    Research Coordinators. Allergan and ACADIA shall each appoint an individual to act
as the research coordinator for such party (each, a “Research Manager”). The Research Managers shall be the primary contact for the parties regarding the activities 

***Confidential Treatment Requested 

  
 3 

 
contemplated by this Seventh Amendment and shall facilitate all such activities hereunder. The initial Research Manager for Allergan shall be Daniel Gil and the initial Research Manager for
ACADIA shall be Ethan Burstein. Each party may replace its Research Manager with another individual at any time with prior written notice to the other party. Each Research Manager who is not otherwise a member of the JRC shall be permitted to attend
meetings of the JRC. 
 5.    Patent Costs. In the event that Allergan selects a Back-up Pool compound to be
treated as a Collaboration Lead Compound pursuant to Section 1 above, then Allergan shall reimburse ACADIA for [...***...] of all reasonable out of pocket legal expenses incurred by ACADIA that are associated with the filing and
prosecuting of (i) all Collaboration Patents having one or more claims covering such compound, and (ii) any ACADIA Patents having one or more claims covering such compound. (Capitalized terms used in this paragraph that are not defined
have the meaning given to such terms in the 1999 Agreement). 
 6.    Bankruptcy. All rights and licenses
granted under the 1997 Agreement, the 1999 Agreement, the 2003 Agreement, and any amendments to those agreements will be considered for purposes of Section 365(n) of 11 U.S.C. (the “Bankruptcy Code”) licenses of rights
to “intellectual property” as defined under Section 101(56) of the Bankruptcy Code. The parties agree that a licensee of such rights under those agreements will retain and may fully exercise all of its rights and elections under the
Bankruptcy Code. In the event that a licensor seeks or is involuntarily placed under the protection of the Bankruptcy Code, and the trustee in bankruptcy rejects any of those agreements, the licensee hereby elects, pursuant to Section 365(n),
to retain all rights granted to it under those agreements to the extent permitted by law. 
 7.    Full Force and
Effect. Except as it may specifically be amended by this Seventh Amendment, each of the 1997 Agreement, the 1999 Agreement, the 2003 Agreement, and any amendments to those agreements, shall remain in full force and effect. If there is any
inconsistency or conflict between any provision in this Seventh Amendment and any of the foregoing agreements, as amended to date, the provision in this Seventh Amendment shall control. 
 8.    Miscellaneous. This Seventh Amendment may be signed in counterparts, each of which shall be deemed an original, all of which taken together shall be deemed one
instrument. This Seventh Amendment shall be governed by the laws of the State of California as such laws are applied to contracts entered into or to be performed entirely within such state. 

***Confidential Treatment Requested 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have duly
executed this SEVENTH AMENDMENT TO COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE
AGREEMENTS. 
  

									
	ACADIA PHARMACEUTICALS INC.	 		 	 ALLERGAN SALES, LLC, a Delaware limited

		 		 	liability company, a successor in interest of
	By:	 	/s/    THOMAS H. AASEN        	 		 	VISION PHARMACEUTICALS L.P.,
	Name:	 	Thomas H. Aasen	 		 	A Texas limited partnership, dba Allergan,
	Title:	 	 Executive Vice President, Chief
 Business Officer and Chief
 Financial Officer
	 		 	by Allergan General, Inc.,
		 	 		 	its general partner
					
		 		 		 	By:	 	/s/    SCOTT M. WHITCUP        
					
		 		 		 	Name:	 	Scott M. Whitcup
		 		 		 	  
 Title:
	 	  
 Executive Vice President, Chief Scientific
Officer

		 		 		 	  
 Guarantee of performance by:

 
 ALLERGAN, INC.

					
		 		 		 	By:	 	/s/    SCOTT M. WHITCUP        
					
		 		 		 	Name:	 	Scott M. Whitcup
					
		 		 		 	Title:	 	Executive Vice President, Chief Scientific Officer

  
 5 

 Exhibit A 
 List of Compounds Currently in Back-up Pool 
 [...***...] 

***Confidential Treatment Requested 

  
 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}]]